RxSight, Inc.
RXST
$12.62
-$0.47-3.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.75% | 27.68% | 46.69% | 57.08% | 67.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.75% | 27.68% | 46.69% | 57.08% | 67.51% |
| Cost of Revenue | -12.18% | 1.74% | 12.72% | 16.06% | 22.49% |
| Gross Profit | 21.32% | 40.89% | 66.32% | 84.03% | 101.70% |
| SG&A Expenses | 19.88% | 26.69% | 30.29% | 35.43% | 35.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.07% | 20.34% | 24.48% | 27.03% | 27.95% |
| Operating Income | -16.38% | -0.39% | 22.66% | 26.41% | 27.93% |
| Income Before Tax | -16.25% | 12.45% | 40.44% | 43.60% | 44.23% |
| Income Tax Expenses | 260.00% | 294.74% | 103.45% | 150.00% | -53.49% |
| Earnings from Continuing Operations | -16.41% | 12.29% | 40.34% | 43.52% | 44.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.41% | 12.29% | 40.34% | 43.52% | 44.23% |
| EBIT | -16.38% | -0.39% | 22.66% | 26.41% | 27.93% |
| EBITDA | -21.68% | -2.65% | 22.56% | 27.66% | 30.45% |
| EPS Basic | -7.15% | 20.87% | 46.68% | 49.93% | 52.45% |
| Normalized Basic EPS | -7.01% | 17.78% | 44.55% | 48.18% | 51.02% |
| EPS Diluted | -7.15% | 20.87% | 46.68% | 49.93% | 52.45% |
| Normalized Diluted EPS | -7.01% | 17.78% | 44.55% | 48.18% | 51.02% |
| Average Basic Shares Outstanding | 7.63% | 9.85% | 11.29% | 12.84% | 16.38% |
| Average Diluted Shares Outstanding | 7.63% | 9.85% | 11.29% | 12.84% | 16.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |